BR112017003486A2 - methods for expressing an antigenic molecule or a portion thereof and generating an immune response, pharmaceutical composition, cell or cell population, uses of a cell population and antigenic molecule, antigenic molecule, photosensitizing agent and cytokine, product, and kit - Google Patents
methods for expressing an antigenic molecule or a portion thereof and generating an immune response, pharmaceutical composition, cell or cell population, uses of a cell population and antigenic molecule, antigenic molecule, photosensitizing agent and cytokine, product, and kitInfo
- Publication number
- BR112017003486A2 BR112017003486A2 BR112017003486-7A BR112017003486A BR112017003486A2 BR 112017003486 A2 BR112017003486 A2 BR 112017003486A2 BR 112017003486 A BR112017003486 A BR 112017003486A BR 112017003486 A2 BR112017003486 A2 BR 112017003486A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- cells
- antigenic molecule
- cytokine
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201415247A GB201415247D0 (en) | 2014-08-28 | 2014-08-28 | Compound and method |
| GB1415247.4 | 2014-08-28 | ||
| GB1420773.2 | 2014-11-21 | ||
| GB201420773A GB201420773D0 (en) | 2014-11-21 | 2014-11-21 | Compound and method |
| PCT/EP2015/069794 WO2016030529A1 (en) | 2014-08-28 | 2015-08-28 | Compound and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017003486A2 true BR112017003486A2 (en) | 2018-01-16 |
Family
ID=54065872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017003486-7A BR112017003486A2 (en) | 2014-08-28 | 2015-08-28 | methods for expressing an antigenic molecule or a portion thereof and generating an immune response, pharmaceutical composition, cell or cell population, uses of a cell population and antigenic molecule, antigenic molecule, photosensitizing agent and cytokine, product, and kit |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10537639B2 (https=) |
| EP (1) | EP3185901B1 (https=) |
| JP (2) | JP2017526371A (https=) |
| KR (1) | KR102678732B1 (https=) |
| CN (1) | CN108136016A (https=) |
| AU (1) | AU2015308345B9 (https=) |
| BR (1) | BR112017003486A2 (https=) |
| NZ (1) | NZ729408A (https=) |
| WO (1) | WO2016030529A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109912607B (zh) * | 2018-12-11 | 2021-01-22 | 南华大学 | 一类卟啉-白杨素复合物及其抗肿瘤活性 |
| JP7288951B2 (ja) | 2019-02-19 | 2023-06-08 | 大塚電子株式会社 | 光線力学的療法条件パラメータの決定方法および光線力学的療法装置 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO180167C (no) | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
| GB9905911D0 (en) | 1999-03-15 | 1999-05-05 | Photocure As | Method |
| KR100980153B1 (ko) | 2000-11-29 | 2010-09-03 | 피씨아이 바이오테크 에이에스 | 사이토졸 내로의 분자 전달을 위한 광화학적 내부이행 |
| AU2002230693B2 (en) | 2000-12-13 | 2006-08-17 | Immunex Corporation | Method for generating immortal dendritic cell lines |
| GB0121023D0 (en) | 2001-08-30 | 2001-10-24 | Norwegian Radium Hospital Res | Compound |
| ES2623812T3 (es) * | 2003-11-12 | 2017-07-12 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Vectores a medida para tratar y prevenir cáncer pancreático |
| WO2005097976A1 (ja) * | 2004-04-06 | 2005-10-20 | Ehime University | 抗原パルスして得られた樹状細胞 |
| WO2005100547A1 (ja) * | 2004-04-06 | 2005-10-27 | Techno Network Shikoku Co., Ltd. | 抗原パルスして得られた樹状細胞 |
| EP2307047A4 (en) * | 2008-06-06 | 2011-09-07 | Baylor Res Inst | RESPIRATORY SYNCYTIAL VIRUS MAKES TOLEROGENIC DENDRITIC CELLS |
| US20120269765A1 (en) | 2009-07-24 | 2012-10-25 | Garcia K Christopher | Cytokine compositions and methods of use thereof |
| GB201208548D0 (en) * | 2012-05-15 | 2012-06-27 | Pci Biotech As | Compound and method |
| CA2906279A1 (en) * | 2013-03-15 | 2014-09-18 | Pci Biotech As | A method of generating antigen presenting cells using photochemical internalisation |
| JP6684215B2 (ja) * | 2013-08-28 | 2020-04-22 | ピーシーアイ バイオテック エイエス | 予防接種用化合物および免疫化用化合物、ならびに予防接種方法および免疫化方法 |
| WO2015028575A1 (en) * | 2013-08-28 | 2015-03-05 | Pci Biotech As | Immunisation method by photochemical internalisation |
| AU2014390262B2 (en) * | 2014-04-11 | 2020-11-26 | Pci Biotech As | Method of treating melanoma |
-
2015
- 2015-08-28 EP EP15760426.5A patent/EP3185901B1/en active Active
- 2015-08-28 US US15/506,453 patent/US10537639B2/en active Active
- 2015-08-28 BR BR112017003486-7A patent/BR112017003486A2/en active Search and Examination
- 2015-08-28 CN CN201580055883.9A patent/CN108136016A/zh active Pending
- 2015-08-28 JP JP2017511702A patent/JP2017526371A/ja active Pending
- 2015-08-28 AU AU2015308345A patent/AU2015308345B9/en not_active Ceased
- 2015-08-28 WO PCT/EP2015/069794 patent/WO2016030529A1/en not_active Ceased
- 2015-08-28 NZ NZ729408A patent/NZ729408A/en not_active IP Right Cessation
- 2015-08-28 KR KR1020177008280A patent/KR102678732B1/ko active Active
-
2020
- 2020-07-17 JP JP2020123157A patent/JP7079819B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3185901C0 (en) | 2023-10-04 |
| EP3185901A1 (en) | 2017-07-05 |
| KR102678732B1 (ko) | 2024-06-25 |
| AU2015308345B9 (en) | 2020-12-24 |
| CN108136016A (zh) | 2018-06-08 |
| WO2016030529A1 (en) | 2016-03-03 |
| JP2017526371A (ja) | 2017-09-14 |
| CA2959207A1 (en) | 2016-03-03 |
| US20170252441A1 (en) | 2017-09-07 |
| JP2020182486A (ja) | 2020-11-12 |
| EP3185901B1 (en) | 2023-10-04 |
| KR20170047336A (ko) | 2017-05-04 |
| NZ729408A (en) | 2021-12-24 |
| US10537639B2 (en) | 2020-01-21 |
| AU2015308345B2 (en) | 2020-12-10 |
| JP7079819B2 (ja) | 2022-06-02 |
| AU2015308345A1 (en) | 2017-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3038619B1 (en) | Compound and method for vaccination and immunisation | |
| Håkerud et al. | Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen | |
| EP3265120B1 (en) | Method | |
| US8834899B2 (en) | Photodynamic therapy-generated mesothelioma vaccine | |
| Haug et al. | Photochemical internalization of peptide antigens provides a novel strategy to realize therapeutic cancer vaccination | |
| AU2018229741A1 (en) | Peptides and methods for the treatment of diabetes | |
| JP7079819B2 (ja) | 化合物および方法 | |
| US20160040128A1 (en) | Method | |
| Liu et al. | Rabies virus lipopeptide conjugated to a TLR7 agonist improves the magnitude and quality of the Th1-biased humoral immune response in mice | |
| CA2945220C (en) | Method of treating melanoma | |
| WO2015028575A1 (en) | Immunisation method by photochemical internalisation | |
| WO2014176604A1 (en) | Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis | |
| CA2959207C (en) | Expression of an antigenic molecule on the surface of a cell using a photosensitizing agent and a cytokine | |
| JPH07504662A (ja) | 免疫無防備状態の宿主における治療用途のための免疫促進剤 | |
| CA2557654A1 (en) | Peptides of il1 beta and tnf alpha and method of treatment using same | |
| WO2016030528A1 (en) | Compound and method | |
| CN103495157B (zh) | 一种dc疫苗及其制备方法和应用 | |
| RU2021816C1 (ru) | Способ получения вакцины против холеры | |
| WO2015130488A2 (en) | Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 41/00 (2006.01), A61K 47/00 (2006.01), C12N 5 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |